SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1869-6961
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes ; volume:11 ; number:12 ; day:29 ; month:9 ; year:2020 ; pages:2757-2774 ; date:12.2020
Diabetes therapy ; 11, Heft 12 (29.9.2020), 2757-2774, 12.2020

Creator
Wheeler, David C.
James, June
Patel, Dipesh
Viljoen, Adie
Ali, Amar
Evans, Marc
Fernando, Kevin
Hicks, Debbie
Milne, Nicola
Newland-Jones, Philip
Wilding, John
Contributor
SpringerLink (Online service)

DOI
10.1007/s13300-020-00930-x
URN
urn:nbn:de:101:1-2020121818373271477508
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:29 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Wheeler, David C.
  • James, June
  • Patel, Dipesh
  • Viljoen, Adie
  • Ali, Amar
  • Evans, Marc
  • Fernando, Kevin
  • Hicks, Debbie
  • Milne, Nicola
  • Newland-Jones, Philip
  • Wilding, John
  • SpringerLink (Online service)

Other Objects (12)

Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?

Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?

Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease

Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease

Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape

Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape

Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study

Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study

SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease

SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease

Direct cardiac effects of SGLT2 inhibitors

Direct cardiac effects of SGLT2 inhibitors

Is There a Role for SGLT2 Inhibitors in Patients with End-Stage Kidney Disease?

Is There a Role for SGLT2 Inhibitors in Patients with End-Stage Kidney Disease?

SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease

SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease

The Treatment Effectiveness Evaluation for Slowing the Progression of Diabetic Nephropathy During Stage 4 Chronic Kidney Disease

The Treatment Effectiveness Evaluation for Slowing the Progression of Diabetic Nephropathy During Stage 4 Chronic Kidney Disease

SGLT2-Inhibitoren – Effektive Blutzuckerregulation über die Niere

SGLT2-Inhibitoren – Effektive Blutzuckerregulation über die Niere

Comparison of incident hypertension between SGLT2 inhibitors vs. DPP4 inhibitors

Comparison of incident hypertension between SGLT2 inhibitors vs. DPP4 inhibitors

Correction to: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease

Correction to: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease

Related objects